Efficacy and safety of FOLFIRINOX in elderly patients with advanced pancreatic adenocarcinoma.

被引：0
|
作者：
Jung, Jae Hyup
Kang, Jingu
Lee, Jong-Chan
Hwang, Jin-Hyeok
机构：
[1] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea
[2] Hallym Univ, Med Ctr, Dept Internal Med, Seoul, South Korea
[3] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Seongnam, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e15729
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15729
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis
    Baldini, C.
    Escande, A.
    Bouche, O.
    El Hajbi, F.
    Volet, J.
    Bourgeois, V.
    Vantroys, T. Renaut
    Ploquin, A.
    Desauw, C.
    Hebbar, M.
    PANCREATOLOGY, 2017, 17 (01) : 146 - 149
  • [2] Folfirinage: Tolerance and efficacy of folfirinox in elderly patients with advanced pancreatic adenocarcinoma
    Baldini, C.
    Escande, A.
    Bouche, O.
    Bourgeois, V.
    Renaut-Vantroys, T.
    Ploquin, A.
    Desauw, C.
    Hebbar, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S196 - S196
  • [3] Safety and efficacy of modified dose-attenuated FOLFIRINOX chemotherapy in patients over 65 years with advanced pancreatic adenocarcinoma.
    Alessandretti, Matheus Bongers
    Brandao, Erika Pereira
    Abrahao, Carina Meira
    Lino, Aline Rocha
    Macambira Junior, Rodnei
    Costa, Marcos Andre
    Cruz, Marcelo Rocha
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Safety and efficacy of modified dose-attenuated FOLFIRINOX chemotherapy in patients over 65 years with advanced pancreatic adenocarcinoma.
    Alessandretti, Matheus Bongers
    Moreira, Raphael Brandao
    Brandao, Erika Pereira
    Gomes, Jessica Ribeiro
    Fernandes Amarante, Marcus Paulo
    Lino, Aline Da Rocha
    Martins Junior, Rodnei Merlrina
    Abrahao, Carina Mina
    Soares de Sousa, Tarcia Tarciane
    Peixoto, Renata D'Alpino
    Cruz, Marcelo Rocha
    Maluf, Fernando C.
    Buzaid, Antonio C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [5] Neoadjuvant FOLFIRINOX and/or gemcitabine/nabpaclitaxel for advanced pancreatic adenocarcinoma.
    Turner, Keli
    Narayanan, Sumana
    Attwood, Kristopher
    Hochwald, Steven N.
    Iyer, Renuka V.
    Kukar, Moshim
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [6] FOLFIRINOX and gemcitabine/nab-paclitaxel efficacy in the treatment of locally advanced unresectable pancreatic adenocarcinoma.
    Bednar, Filip
    Ocuin, Lee Mayer
    Steve, Jennifer
    Zenati, Mazen S.
    Winters, Sharon
    Hogg, Melissa Ellen
    Bahary, Nathan
    Zeh, Herbert J.
    Zureikat, Amer H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [7] Gemcitabine versus FOLFIRINOX in patients with advanced hENT1+ve pancreatic adenocarcinoma.
    Calegari, Maria Alessandra
    Orlandi, Armando
    Indellicati, Giulia
    Martini, Maurizio
    Cocomazzi, Alessandra
    Bagala, Cinzia
    Zurlo, Valeria
    Di Dio, Carmela
    Barile, Rosalba
    Monterisi, Santa
    Cassano, Alessandra
    Astone, Antonio
    Barone, Carlo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] FOLFIRINOX FOR LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA. RESULTS OF AN AGEO MULTICENTRIC PROSPECTIVE STUDY
    Marthey, L.
    Sa-Cunha, A.
    Blanc, J. F.
    Cueff, A.
    Francois, E.
    Trouilloud, I.
    Malka, D.
    Bachet, J.
    Coriat, R.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 238 - 238
  • [9] Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma
    Gilabert, Marine
    Chanez, Brice
    Rho, Young Soo
    Giovanini, Marc
    Turrini, Olivier
    Batist, Gerald
    Kavan, Petr
    Raoul, Jean Luc
    MEDICINE, 2017, 96 (16)
  • [10] Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience
    Ghorani, Ehsan
    Wong, Han Hsi
    Hewitt, Carole
    Calder, Joanna
    Corrie, Pippa
    Basu, Bristi
    ONCOLOGY, 2015, 89 (05) : 281 - 287
12345